MOUNTAIN VIEW, Calif. & GOTHENBURG, Sweden – Glooko’s Mobile Insulin Dosing System can help improve glycemic control of people with Type 2 diabetes, a recent three-week study showed. MIDS decreased mean blood glucose, reduced the rate of hyperglycemic events and increased in-range blood glucose readings of participants, according to the study. “We are thrilled to see early clinical evidence show the positive impact the Glooko Mobile Insulin Dosing System can have on people with diabetes,” said Rick Altinger, CEO of Glooko, a provider of diabetes data management solutions, in a statement. The goal of the MIDS mHealth application, which is currently available only for investigational use, is to improve glycemic outcomes and increase adherence to a long-acting insulin regimen.
You are here: / / Glooko’s mHealth app improves glycemic control in people with diabetes